S. aureus colonization and clinical symptoms remain stable upon topical XZ.700 treatment: Results of a double‐blind randomized clinical trial in patients with mild to moderate atopic dermatitis
British Journal of Clinical Pharmacology · 2026-10 · 92 (10) · 3448-3459
DOI: 10.1002/bcp.70630 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 10.06.2026. Verfasst von Laura W J van der Meulen und 13 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Human Drug Research, Leiden, the Netherlands. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Dermatitis, Atopic, Endopeptidases, Staphylococcus aureus. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Micreos Human Health B.V..
Abstract (Originalsprache)
Aim
Recovering dysbiosis may improve atopic dermatitis (AD) symptoms. XZ.700 is a recombinant chimeric endolysin that specifically targets Staphylococcus aureus and could be a new treatment option for patients with AD. The aim of this first‐in‐human study was to evaluate the safety, tolerability and efficacy of topical XZ.700 and explore the pharmacodynamic effects in patients with mild to moderate AD. Method and Materials This study consisted of Part A and Part B. In Part A, subjects were randomized and received XZ.700 10 μg/g, XZ.700 30 μg/g, XZ.700 100 μg/g or vehicle twice daily for 7 days on nonlesional skin and on all lesions (1% ≤ BSA ≤ 10%). In Part B, subjects received XZ.700 100 μg/g or vehicle on all lesions twice daily for 14 days (1% ≤ BSA ≤ 15%). Clinical scores and patient‐reported outcomes were recorded. Pharmacodynamic measurements were taken.
Results
In total, 35 patients completed the study. Tolerability of XZ.700 was acceptable. XZ.700 100 μg/g showed no evidence of effect on cultured S. aureus (estimated difference −52.9% CFU/mL; 95% CI −88.4% to 90.8%), oSCORAD (1.03; 95% CI −5.20 to 7.26) or EASI (−0.534; 95% CI −2.48 to 1.41). Furthermore, XZ.700 treatment did not result in a significant reduction in the relative abundance of S. aureus via metagenomics or other pharmacodynamic outcomes.
Conclusion
Tolerability and safety of short‐term topical administration of XZ.700 100 μg/g for 14 days were acceptable in most participants; however, some local application‐site events occurred, and one hypersensitivity reaction led to discontinuation. XZ.700 did not demonstrate target engagement or clinical benefit vs . vehicle under the tested conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Human Drug Research, Leiden, the Netherlands.
- Leiden University Medical Center, Leiden, the Netherlands.
- Clinical Microbiomics A/S, Copenhagen, Denmark.
- Regional Public Health Laboratory Kennemerland, Haarlem, the Netherlands.
- Micreos Human Health, Bilthoven, the Netherlands.
- Department of Dermatology, Erasmus Medical Centre, Rotterdam, the Netherlands.
ORCID-Profile: Robert Rissmann
Förderung
- Micreos Human Health B.V.
Zitieren
APA
van der Meulen, L. W. J., Bergmans, M. E., Assil, S., Klarenbeek, N., de Kam, M. L., Tibboel, A. J., Brach, T., Herpers, B. L., Frieling, J., de Jong, V., Freyee, B., van Doorn, M. B. A., Rissmann, R., & Niemeyer-van der Kolk, T. (2026). S. aureus colonization and clinical symptoms remain stable upon topical XZ.700 treatment: Results of a double‐blind randomized clinical trial in patients with mild to moderate atopic dermatitis. British Journal of Clinical Pharmacology, 92(10), 3448-3459. https://doi.org/10.1002/bcp.70630
Vancouver
van der Meulen LWJ, Bergmans ME, Assil S, Klarenbeek N, de Kam ML, Tibboel AJ, et al. S. aureus colonization and clinical symptoms remain stable upon topical XZ.700 treatment: Results of a double‐blind randomized clinical trial in patients with mild to moderate atopic dermatitis. British Journal of Clinical Pharmacology. 2026;92(10):3448-3459. doi:10.1002/bcp.70630
BibTeX
@article{vanderMeulen2026,
author = {van der Meulen, Laura W J and Bergmans, Menthe E and Assil, Salma and Klarenbeek, Naomi and de Kam, Marieke L and Tibboel, Alexa J and Brach, Thorsten and Herpers, Bjorn L and Frieling, Johan and de Jong, Vincent and Freyee, Benthe and van Doorn, Martijn B A and Rissmann, Robert and Niemeyer-van der Kolk, Tessa},
title = {S. aureus colonization and clinical symptoms remain stable upon topical XZ.700 treatment: Results of a double‐blind randomized clinical trial in patients with mild to moderate atopic dermatitis},
journal = {British Journal of Clinical Pharmacology},
year = {2026},
volume = {92},
number = {10},
pages = {3448--3459},
doi = {10.1002/bcp.70630}
}
EUVIMED